United States: Supreme Court Clarifies That Judges, Not Juries, Must Determine Whether FDA Actions Preempt State Failure-To-Warn Claims Against Drug Manufacturers

Last Updated: June 11 2019
Article by Ropes & Gray LLP

On May 20, 2019, the U.S. Supreme Court ruled in Merck Sharpe & Dohme Corp. v. Albrecht that, in analyzing whether a state law failure-to-warn claim against a drug manufacturer is preempted by federal law, the question of FDA “disapproval” of a proposed warning is for a judge, not a jury, to decide. In a 2009 case, Wyeth v. Levine, the Court stated that federal preemption would be established if a drug manufacturer could demonstrate by “clear evidence” that it would be “impossible” to provide the warning the plaintiff claims to be necessary to avoid state tort liability without violating federal (FDA) requirements. Justice Breyer’s majority opinion in Albrecht, joined by five other justices, held that this standard is met when a judge determines that “the drug manufacturer fully informed FDA of the justifications for the warning required by state law and . . . the FDA, in turn, informed the drug manufacturer that the FDA would not approve a change to the drug’s label to include that warning.” Justice Thomas wrote a separate concurring opinion, and Justice Alito, joined by Justices Roberts and Kavanaugh, wrote an opinion concurring in the judgment.

While drug manufacturers will likely welcome the majority opinion’s conclusion that judges are better equipped than juries to opine on complicated FDA regulatory questions, the Court’s explanation of how the “clear evidence” standard can be met suggests that manufacturers will not often be able to satisfy it. Thus, preemption of state law failure to warn claims against drug manufacturers is likely to remain an infrequent exception to the general rule of no preemption.

Legal and Factual Background

In Wyeth v. Levine, the Court held that FDA’s approval of a warning in a drug’s labeling did not bar state law tort claims alleging that the labeling was inadequate. The Court noted that although FDA approves a new drug’s labeling, the manufacturer retains primary responsibility for ensuring its adequacy. Because the manufacturer could have strengthened or added warnings to its FDA-approved drug labeling under FDA’s “Changes Being Effected” (CBE) regulation prior to receiving FDA approval of a labeling change, the Court determined it was possible for the manufacturer to satisfy both state tort law and federal labeling requirements. Therefore, the Court ruled, the manufacturer was not entitled to impossibility preemption. At the same time, the Court acknowledged that a state law failure-to-warn claim would be preempted if there were “clear evidence” that FDA would not have approved the warning that state law requires.

Albrecht involved claims by hundreds of plaintiffs who used Merck’s osteoporosis drug Fosamax and alleged that Merck failed to adequately warn them of the heightened risk of atypical femoral fractures caused by the drug. The factual record demonstrated, however, that Merck had provided FDA with information about these types of fractures and had unsuccessfully sought FDA approval to add a warning about them in the drug’s labeling. 

Specifically, in 2008, Merck submitted a Prior Approval Supplement (PAS) proposing to add discussion of “low-energy femoral shaft fractures” to the Warnings and Precautions and Adverse Reactions sections of the labeling, with multiple references to “stress fractures.” In a 2009 Complete Response Letter (CRL), FDA agreed that the change to the Adverse Reactions section was warranted (with minor modifications), but rejected the proposed changes to the Warnings and Precautions section. The CRL stated, among other things, that discussing “the risk factors for stress fractures” was “not adequately supported by the available literature and post-marketing adverse event reporting.” Merck then proceeded to update the Adverse Reactions section of the labeling via a CBE supplement, but not the Warnings and Precautions section, consistent with FDA’s CRL. In litigation, Merck argued that FDA’s rejection of the proposed Warnings and Precautions language meant that the agency would have rejected an attempt to add a warning relating to atypical femoral fractures via the CBE process (prior to October 2010, when FDA eventually concluded that a warning was appropriate). Thus, Merck argued, it would have had to violate federal law to provide the warning that plaintiffs argued was required to avoid liability under state law. The district court agreed and held that the plaintiffs’ failure-to-warn claims were preempted. 

The Third Circuit reversed on appeal. The court construed the “clear evidence” standard from Levine to impose a heightened burden of proof for preemption that demands a manufacturer present “clear and convincing” evidence that it was “highly probable” that FDA would not have approved a change to the drug’s labeling. The court also held that whether this burden is met presents a question of fact that ought to be decided by a jury, not a judge. Seizing on ambiguity in the language of FDA’s CRL to Merck, the plaintiffs argued that the agency did not conclude that any new warning about atypical femoral fractures was unsupported by the evidence, but only that Merck’s particular proposal, which used the broader term “stress fractures” rather than “atypical femoral fractures,” was not appropriate. While the Third Circuit did not completely discount the argument that FDA could have proposed alternative language had it concluded that a new warning was warranted, the court nevertheless held that plaintiffs had provided sufficient evidence for a reasonable juror to conclude that FDA would have approved a properly worded warning relating to atypical femoral fractures.

The Supreme Court’s Decision

The Supreme Court vacated and remanded the Third Circuit’s decision for further proceedings, finding that the Third Circuit incorrectly treated preemption as a question of fact for a jury, rather than a question of law for a judge. Although the Court declined to decide the merits of Merck’s preemption defense on the facts presented, the majority opinion’s discussion of the type of evidence that may constitute “clear evidence” of impossibility provides guidance to lower courts assessing such preemption arguments. Specifically, Justice Breyer’s majority opinion sets forth several key principles:

  • “Clear evidence” that federal law prohibited a manufacturer from adding a warning to a drug’s labeling requires the manufacturer to show that (i) it fully informed FDA of the justifications for the warning, and (ii) FDA, in turn, notified the manufacturer that it would not approve a labeling change to include that warning.
  • A manufacturer will “not ordinarily” be able to meet the clear evidence requirement because the CBE regulation permits a firm to make labeling changes, without prior approval, to add or strengthen warnings to reflect newly acquired information.
  • The only agency actions that may constitute clear evidence are those taken “pursuant to the FDA’s congressionally delegated authority.” FDA may communicate its disapproval of a warning in one of three ways: (i) notice and comment rulemaking setting forth specific labeling standards, (ii) rejection of a warning via issuance of a CRL in response to a new drug application or supplement, or (iii) “other agency action carrying the force of law,” such as an exercise of FDA’s statutory authority to order safety-related labeling changes under 21 U.S.C. § 355(o)(4)(A).
  • In this context, the existence of “clear evidence” that FDA would have refused to approve a warning is not an evidentiary question for a jury. The relevant question is instead “whether the relevant federal and state laws irreconcilably conflict.” Because judges are normally familiar with administrative law and are generally better equipped than juries to evaluate agency determinations, preemption is a question of law for a judge to decide. Related factual questions are “subsumed” within the legal analysis.

In a separate concurring opinion, Justice Thomas stated that he would reject Merck’s preemption argument because “neither agency musings nor hypothetical future rejections” qualify as “Laws” capable of preemption. In contrast to the majority’s view that a CRL could have preemptive effect because federal law authorizes FDA to communicate its disapproval of a warning through such a letter, Justice Thomas reasoned that a CRL is technically not a final agency action and therefore cannot have preemptive effect.

Justice Alito, in a separate opinion concurring in the judgment, which was joined by Justices Roberts and Kavanaugh, agreed with the majority that preemption is a question of law for a judge to decide. But Justice Alito sharply criticized the majority opinion’s potentially “misleading” discussion of the law and the facts. Among other things, Justice Alito noted that the majority failed to discuss the implications for preemption of FDA’s statutory authority to order safety-related labeling changes under 21 U.S.C. § 355(o)(4)(A), which was enacted in 2007. Justice Alito “assume[s]” that the Third Circuit will consider this issue on remand.

Takeaways for Drug Manufacturers

The ramifications of Albrecht are likely to be limited only to branded drug manufacturers, not generic drug manufacturers. In 2011, in PLIVA v. Mensing, the Court held that because a generic drug is required to bear the same labeling as its brand name counterpart and because generic drug manufacturers cannot add or strengthen warnings via the CBE process, state failure to-warn claims are preempted on the basis of impossibility. Nothing about Albrecht changes this analysis.

For branded drug manufacturers, Albrecht represents an incremental expansion of the Court’s preemption jurisprudence. Although Justice Breyer’s majority opinion clarifies and builds upon the prior holding of Levine, it nevertheless leaves unanswered questions for lower courts to grapple with in the future. For example, as alluded to by Justice Alito’s opinion concurring in the judgment, the significance of FDA’s statutory authority to order safety-related labeling changes may be highly relevant to the preemption analysis in certain cases. Under 21 U.S.C. § 355(o)(4)(A), if FDA becomes aware of new information that it determines should be included in the labeling of a drug, FDA “shall” notify the drug manufacturer and initiate a labeling change. In circumstances where FDA learns of information regarding a new risk—whether from the manufacturer, a citizen petition by a third party, or FDA’s own analysis—and declines to require a labeling change, the “logical conclusion” according to Justice Alito is that FDA determined that a change was unwarranted. Yet Justice Alito does not address how one would determine when FDA stopped evaluating a potential safety risk and conclusively declined to require a labeling change, suggesting that these would be highly fact-dependent decisions. Justice Breyer’s majority opinion does not squarely address whether this type of implicit disapproval could constitute an agency action with the force of law sufficient to have preemptive effect.

Going forward, branded drug manufacturers engaging with FDA regarding new safety information and potential labeling changes should be mindful that informal agency feedback and correspondence (e.g., meeting minutes or emails reflecting an FDA employee’s view that a particular warning may not be warranted) are unlikely to be sufficient to have preemptive effect. Where a manufacturer and FDA disagree on a proposed warning, forcing FDA either to approve the warning or reject it via issuance of a CRL may often be the prudent course of action.

If you have any questions about this decision, please contact any member of Ropes & Gray’s FDA regulatory practice or your usual Ropes & Gray advisor.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions